Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
15.97 CNY +0.38% Intraday chart for Zhejiang AngLiKang Pharmaceutical CO.,LTD. +10.44% -26.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022 CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List MT
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan MT
Zhejiang Anglikang Pharma to Boost Stake in Local Biopharma Firm to 62% For 191 Million Yuan MT
Zhejiang AngLiKang Pharmaceutical CO.,LTD. completed the acquisition of an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. signed a share transfer agreement to acquire an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin for approximately CNY 191.3 million. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Announces Implementation of Final Profit Distribution Plan on A Shares for the Year 2021, Payable on 20 June 2022 CI
Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.
More charts
Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a China-based company principally engaged in the research, development, production and sales of chemical raw materials and preparations. The Company's products mainly include cephalosporin and penicillin series, anti-hypertension series, digestive system series, kidney disease series and others.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002940 Stock
  4. News Zhejiang AngLiKang Pharmaceutical CO.,LTD.
  5. Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets